Biotech Values

[genisi]

You are right of course that it is known for some time now that IL28B status is an irrelevant factor when you treat HCV with a potent DAA combo and perhaps (not sure about that) GILD were still genotyping the IL28 locus, but even if so, it would be a response predictor for INF containing treatment (predicts viral clearance) not INF intolerance. So my feeling is that these patients are a bit more intolerant to treatments in general and naïve comply better.